PDGF-D Activators
The chemical class of PDGF-D activators encompasses a diverse set of compounds that can modulate PDGF-D expression and function through various signaling pathways and cellular processes. These activators target key nodes within interconnected cellular networks, showcasing the potential for targeted interventions to influence PDGF-D in diverse biological contexts. One subgroup includes tyrosine kinase inhibitors like Axitinib and Imatinib, which directly target PDGFRs. Axitinib disrupts PDGF-D indirectly by inhibiting PDGFR signaling, showcasing the pivotal role of tyrosine kinase pathways in regulating PDGF-D expression. Imatinib, a tyrosine kinase inhibitor with a broader spectrum, further exemplifies the interplay between tyrosine kinase signaling and PDGF-D regulation. Agents like GSK-690693 and LY294002, targeting Akt and PI3K, respectively, showcase the interconnectedness of the PI3K/Akt pathway with PDGF-D. Inhibition of Akt and PI3K can indirectly modulate PDGF-D by disrupting downstream events related to the PI3K/Akt pathway, providing insights into the potential regulatory mechanisms governing PDGF-D expression.
The p38 MAPK inhibitor SB203580 highlights the role of p38 MAPK signaling in PDGF-D regulation. By inhibiting p38 MAPK, SB203580 indirectly influences PDGF-D, showcasing the intricate connections between MAPK pathways and growth factor expression. Protein synthesis inhibitors such as Cycloheximide and proteasome inhibitors like MG-132 underscore the importance of cellular processes in governing PDGF-D expression. Disruption of protein synthesis or proteasomal activity can indirectly impact PDGF-D by altering the turnover of proteins involved in its regulation. Moreover, immunosuppressive drugs like FK506 demonstrate the potential influence of immunomodulatory pathways on PDGF-D expression. FK506's inhibition of calcineurin showcases the interplay between immune responses and growth factor regulation. In summary, the PDGF-D activators represent a class of compounds that can modulate PDGF-D expression and function through diverse molecular mechanisms, including the inhibition of tyrosine kinases, modulation of intracellular signaling pathways, and disruption of key cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $180.00 $726.00 $1055.00 $3350.00 $5200.00 | 23 | |
A769662 is an AMP-activated protein kinase (AMPK) activator. By directly activating AMPK, A769662 influences downstream signaling pathways, including those involved in cellular processes that may impact PDGF-D expression and function indirectly. | ||||||
Tyrphostin AG 879 | 148741-30-4 | sc-3557 sc-3557A | 5 mg 25 mg | $83.00 $328.00 | 4 | |
AG-879 is a potent and selective ErbB2 inhibitor. Its impact on ErbB2 signaling can indirectly influence PDGF-D, as ErbB receptors are involved in interconnected signaling networks, and modulation of ErbB2 can potentially affect cellular responses related to PDGF-D expression. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin is a platinum-containing chemotherapy drug that induces DNA damage. Its impact on cellular stress responses and DNA damage pathways may indirectly influence PDGF-D expression and function, showcasing the potential interplay between cellular stress and growth factor regulation. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide is a protein synthesis inhibitor. Its inhibition of protein synthesis can influence various cellular processes, potentially impacting PDGF-D expression indirectly. The disruption of protein synthesis may affect the synthesis and turnover of proteins involved in PDGF-D regulation. | ||||||
FK-506 | 104987-11-3 | sc-24649 sc-24649A | 5 mg 10 mg | $76.00 $148.00 | 9 | |
FK506 is an immunosuppressive drug that inhibits calcineurin. Its impact on calcineurin signaling can indirectly influence PDGF-D expression, as calcineurin is involved in interconnected signaling pathways, and modulation of calcineurin activity can affect cellular responses related to PDGF-D regulation. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK-690693 is an ATP-competitive Akt kinase inhibitor. Its inhibition of Akt can indirectly influence PDGF-D, as Akt is a key player in the PI3K/Akt signaling pathway, which is interconnected with various cellular processes, and modulation of Akt activity can affect downstream events related to PDGF-D regulation. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL, PDGFR, and c-Kit. Its inhibition of PDGFR signaling can indirectly influence PDGF-D, as it disrupts downstream events related to PDGFR activation, showcasing the interconnectedness of tyrosine kinase signaling pathways and PDGF-D regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a selective PI3K inhibitor. Its impact on PI3K signaling can indirectly influence PDGF-D, as PI3K is a crucial mediator in the PI3K/Akt pathway, which is interconnected with various cellular processes. Modulation of PI3K activity by LY294002 may affect downstream events related to PDGF-D regulation. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG-132 is a proteasome inhibitor. Its inhibition of the proteasome can influence protein degradation pathways and cellular responses. Indirectly, MG-132 may impact PDGF-D by altering the turnover of proteins involved in PDGF-D regulation, showcasing the potential interplay between proteasomal activity and growth factor expression. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a selective p38 MAPK inhibitor. Its impact on p38 MAPK signaling can indirectly influence PDGF-D, as p38 MAPK is involved in interconnected signaling pathways, and modulation of p38 MAPK activity can affect cellular responses related to PDGF-D expression and function. | ||||||